By Product Type (Balloon-Expandable Valves, Self-Expanding Valves, Mechanically Expandable Valves), By Procedure Setting (Inpatient, Outpatient/ASC), By Indication Risk Category (Low Risk, Intermediate Risk, High/Extreme Risk), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers), By Region (Northeast, Midwest, South, West) – Market Size, Industry Analysis, Segmental Insights, Regional Overview, Company Share Analysis, and Market Forecast, 2021–2035
Market Outlook
The US Transfemoral TAVR Device Market is projected to reach approximately USD 14.85 billion by 2035, expanding at a CAGR of 9.7% during the forecast period 2026–2035. The market was valued at USD 5.92 billion in 2025, with historical analysis from 2021 to 2024 demonstrating strong procedural growth driven by expanding indications and clinical acceptance.
Transfemoral access has emerged as the dominant procedural route, accounting for over 92% of total TAVR procedures in the United States, due to its minimally invasive nature, lower complication rates, and faster recovery timelines compared to alternative access routes such as transapical or transaortic.
The US continues to lead globally in TAVR adoption due to a combination of favorable CMS reimbursement, strong structural heart programs, and rapid clinical guideline evolution. The transition of TAVR from high-risk patients to low-risk and younger cohorts is fundamentally reshaping procedural volumes, device innovation cycles, and hospital capital allocation strategies.
Introduction
According to the US Transfemoral TAVR Device Market Report, structural heart interventions are undergoing a paradigm shift, with transfemoral TAVR positioned at the center of this transformation. Severe aortic stenosis remains one of the most prevalent valvular diseases in the aging US population, with more than 2.5 million Americans affected, and a significant proportion remaining untreated due to surgical risk or access limitations.
The evolution of TAVR from a niche intervention to a frontline therapy has been driven by robust clinical evidence, including PARTNER and Evolut trials, demonstrating non-inferiority or superiority to surgical aortic valve replacement (SAVR) across risk categories. Transfemoral access has been pivotal in this transition, enabling shorter hospital stays (often <48 hours), reduced ICU utilization, and improved patient throughput.
The US healthcare system’s shift toward value-based care models further reinforces the economic attractiveness of transfemoral TAVR, particularly in high-volume centers where procedural efficiency and bundled payments are closely monitored.
Key Market Drivers: What’s Fueling the US Transfemoral TAVR Device Market Growth?
Expansion into Low-Risk and Younger Patient Populations
One of the most significant drivers is the clinical expansion of TAVR into low-risk patients, following FDA approvals and guideline updates. Historically limited to inoperable or high-risk patients, TAVR is now increasingly recommended for patients under 75, with ongoing studies evaluating durability in even younger populations.
This expansion is materially increasing procedure volumes and lifetime device demand, as younger patients may require reintervention or valve-in-valve procedures, creating a recurring revenue model for device manufacturers.
Hospital Economics and Procedural Efficiency
Transfemoral TAVR aligns strongly with hospital economic priorities. Compared to SAVR, TAVR reduces:
Length of stay by 40–60%
ICU utilization by up to 70%
Readmission rates in optimized programs
These efficiencies directly translate into improved margins under DRG reimbursement frameworks, making TAVR programs financially attractive for hospitals. As a result, hospitals are increasingly investing in hybrid ORs, imaging systems, and dedicated structural heart teams.
Technological Advancements in Device Design
Continuous innovation in valve design—such as lower profile delivery systems, enhanced sealing skirts, and repositionable valves—has significantly improved procedural outcomes. These advancements are particularly critical for transfemoral access, where vascular complications historically limited adoption.
Next-generation devices are enabling treatment of patients with challenging anatomies, including small annuli, bicuspid valves, and peripheral vascular disease.
Favorable Reimbursement and Policy Support
CMS reimbursement policies have been instrumental in accelerating adoption. Coverage for TAVR procedures is well established, with ongoing refinements to site-of-care policies supporting outpatient TAVR in select patient populations.
Additionally, the expansion of National Coverage Determination (NCD) criteria has increased the number of eligible centers and patients, further driving market growth.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation in the US transfemoral TAVR market is increasingly focused on durability, precision deployment, and procedural simplification.
Manufacturers are investing in:
Next-generation leaflet materials to enhance valve longevity beyond 10–15 years
AI-enabled imaging integration for improved pre-procedural planning
Sheathless delivery systems to reduce vascular complications
Commissural alignment technologies to facilitate future coronary access
A notable trend is the convergence of digital health and structural heart interventions, where procedural data is integrated into hospital analytics platforms to optimize outcomes and reduce variability.
Segmentation Insights
By Product Type
- Balloon-Expandable Valves (Dominant Segment)
Balloon-expandable valves, led by Edwards Lifesciences’ SAPIEN platform, dominate the US market due to their precision deployment and strong clinical track record. These valves are particularly favored in patients requiring accurate positioning and minimal paravalvular leak. - Self-Expanding Valves
Self-expanding valves, such as Medtronic’s Evolut series, are widely used in patients with larger annuli or complex anatomies. Their ability to conform to irregular structures makes them highly versatile. - Mechanically Expandable Valves
Although a smaller segment, mechanically expandable valves offer controlled deployment and repositionability, addressing specific clinical scenarios where precision is critical.
By Procedure Setting
- Inpatient Settings (Dominant)
Most TAVR procedures are still performed in inpatient settings, particularly in high-risk or complex cases. Large academic medical centers dominate this segment due to their advanced infrastructure and multidisciplinary teams. - Outpatient / Ambulatory Surgical Centers (Fastest-Growing)
Outpatient TAVR is emerging as a high-growth segment, supported by improved patient selection, streamlined protocols, and reimbursement evolution. Select centers are achieving same-day discharge, significantly reducing costs.
By Indication Risk Category
- Low-Risk Patients (Fastest-Growing)
This segment is expanding rapidly as clinical evidence supports TAVR as a first-line therapy. The shift toward low-risk patients is a major driver of long-term market expansion. - Intermediate Risk
Intermediate-risk patients remain a core segment, with stable procedural volumes and strong clinical outcomes. - High/Extreme Risk
While historically dominant, this segment is now relatively mature, with slower growth as the market shifts toward earlier intervention.
By End User
- Hospitals (Dominant Segment)
Hospitals account for the majority of procedures due to capital-intensive infrastructure requirements and established structural heart programs. - Cardiac Centers
Specialized cardiac centers are increasingly adopting TAVR, particularly in urban areas with high patient volumes. - Ambulatory Surgical Centers
ASCs represent a nascent but rapidly growing segment, driven by cost containment strategies and procedural standardization.
Regional Insights: Where the Market is Growing Fastest
Regional dynamics in the US transfemoral TAVR market reflect variations in healthcare infrastructure, patient demographics, and procedural maturity.
West (Dominant Region)
The West leads the market, driven by states such as California, Washington, Colorado, and Arizona. California alone accounts for a significant share of national TAVR volumes, supported by:
High concentration of top-ranked cardiac centers (e.g., Cedars-Sinai, Stanford)
Early adoption of structural heart technologies
Strong presence of medtech innovation hubs
The region benefits from high physician expertise and patient awareness, enabling rapid adoption of next-generation devices.
Northeast (High Adoption, Innovation-Driven)
The Northeast, including New York, Massachusetts, and Pennsylvania, is characterized by:
Dense network of academic medical centers
Strong participation in clinical trials
Early adoption of guideline-driven therapies
Institutions such as Mass General and Mount Sinai are leaders in TAVR research and procedural innovation, contributing to high per-capita procedure rates.
South (Fastest-Growing Region)
The South is emerging as the fastest-growing region, driven by:
Large aging population in states like Florida and Texas
Expansion of hospital networks and cardiovascular programs
Increasing access to advanced care in secondary cities
Florida, in particular, has one of the highest TAVR procedure rates per capita, reflecting its demographic profile.
Midwest (Steady Growth, Operational Efficiency Focus)
The Midwest, including Illinois, Ohio, and Michigan, demonstrates steady growth driven by:
Integrated health systems (e.g., Cleveland Clinic, Mayo Clinic)
Focus on operational efficiency and cost optimization
Adoption of standardized TAVR pathways
The region is notable for its emphasis on clinical outcomes and program scalability.
Key Market Players
The US Transfemoral TAVR Device Market is highly concentrated, with a few dominant players and a growing pipeline of emerging innovators.
- Edwards Lifesciences – Market leader with the SAPIEN platform; strong US hospital penetration and continuous product iteration.
- Medtronic – Evolut series drives significant share, particularly in self-expanding valves.
- Abbott Laboratories – Expanding structural heart portfolio with focus on minimally invasive solutions.
- Boston Scientific – Strategic investments in structural heart technologies and pipeline expansion.
- JenaValve Technology – Advancing TAVR solutions for aortic regurgitation.
- Meril Life Sciences (US presence) – Emerging competitor with cost-competitive valve systems.
- MicroPort CardioFlow (US trials) – Expanding clinical footprint in the US.
- Venus Medtech (clinical-stage US expansion) – Focused on global expansion including US regulatory pathways.
- Anteris Technologies – Developing next-generation TAVR valves with biomimetic design.
- Foldax – Polymer-based valve innovation targeting durability.
- Cardiovalve Ltd. – Expanding transcatheter valve solutions.
- Peijia Medical (US trials) – Growing presence through clinical collaborations.
- HighLife SAS (US feasibility studies) – Focus on transcatheter solutions.
- Pi-Cardia – Complementary technologies for valve repair.
- 4C Medical Technologies – Structural heart innovation pipeline.
- Xeltis (US R&D presence) – Regenerative valve technologies.
- ValveXchange – Novel valve replacement concepts.
- Vdyne – Emerging structural heart innovator.
- Hemostemix (adjacent cardiovascular innovation) – Expanding into structural heart space.
- Terumo Corporation (US operations) – Supporting interventional cardiology ecosystem.
- Siemens Healthineers – Imaging platforms critical for TAVR planning.
- GE HealthCare – Advanced imaging and cath lab infrastructure.
- Philips Healthcare – Integrated imaging and procedural guidance systems.
- Canon Medical Systems USA – Imaging solutions supporting TAVR workflows.
- Abbott Structural Heart Division – Expanding interventional cardiology footprint.
Competition is driven by clinical outcomes, ease of use, delivery system profile, and long-term durability data, with hospitals prioritizing vendors offering comprehensive ecosystem solutions.
Recent Developments
Recent developments in the US transfemoral TAVR market highlight continued momentum in clinical adoption and technological innovation.
Expansion of same-day discharge protocols across leading US centers
Increasing use of minimalist TAVR approaches, reducing anesthesia requirements
Ongoing trials evaluating TAVR durability beyond 10 years
FDA approvals for next-generation valve systems with improved sealing and deliverability
Growing integration of AI-driven imaging and procedural planning tools
Conclusion
The US Transfemoral TAVR Device Market is entering a phase of scaled maturity with sustained high growth, driven by clinical expansion, economic alignment, and technological innovation.
As TAVR becomes the default treatment paradigm for aortic stenosis, the market will continue to benefit from:
Expanding patient eligibility
Increasing procedural volumes
Continuous device innovation
The convergence of clinical evidence, reimbursement support, and hospital economics positions transfemoral TAVR as one of the most impactful segments in the US medical device landscape over the next decade.
1. US Transfemoral TAVR Device Market: Market Introduction & Context
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Methodology
1.3.1 Primary Data Collection (Interventional Cardiologists, Structural Heart Teams)
1.3.2 Secondary Data Sources (FDA, CMS, ACC, STS Registries)
1.3.3 External Industry Collaborations
1.3.4 In-House Research Databases
1.3.5 Analytical Frameworks & Forecasting Models
1.3.6 Data Validation & Triangulation
1.4 Key Assumptions (Procedure Growth, ASP Trends, Penetration Rates)
1.5 Market Ecosystem Overview
1.6 Stakeholder Analysis (Device Manufacturers, Hospitals, Cath Labs, ASCs, Payers)
(What this section provides: Foundational understanding of scope, methodology, data reliability, and structural heart ecosystem dynamics in the US TAVR market)
2. US Transfemoral TAVR Device Market: Executive Summary
2.1 Key Insights & Market Snapshot (2025–2035)
2.2 Analyst Viewpoint (Procedure Shift, Site-of-Care Transition)
2.3 Market Attractiveness Index (By Segment & Region)
(What this section provides: Concise strategic overview of market size, growth trajectory, and investment hotspots)
3. US Transfemoral TAVR Device Market: Market Dynamics & Outlook
3.1 Market Drivers
3.1.1 Expansion into Low-Risk Patient Population
3.1.2 Favorable CMS Reimbursement & DRG Economics
3.1.3 Rise of Minimally Invasive Structural Heart Procedures
3.1.4 Aging US Population & Aortic Stenosis Burden
3.2 Market Restraints
3.2.1 High Device Costs & Capital Constraints
3.2.2 Long-Term Durability Concerns in Younger Patients
3.2.3 Access Limitations in Rural Hospitals
3.3 Market Opportunities
3.3.1 Outpatient / Same-Day TAVR Expansion
3.3.2 Valve-in-Valve & Lifetime Management Strategy
3.3.3 AI-Driven Imaging & Procedural Planning
3.4 Patent & Innovation Analysis (2020–2025)
(What this section provides: Deep evaluation of growth drivers, constraints, and emerging strategic opportunities shaping market expansion)
4. US Transfemoral TAVR Device Market: Market Environment & Industry Analysis
4.1 PESTEL Analysis
4.1.1 Political (CMS Policies, FDA Approvals)
4.1.2 Economic (Hospital CapEx, Reimbursement Pressure)
4.1.3 Social (Aging Demographics, Patient Awareness)
4.1.4 Technological (Valve Design, Imaging Integration)
4.1.5 Environmental
4.1.6 Legal (Regulatory Compliance, Clinical Trials)
4.2 Porter’s Five Forces Analysis
4.2.1 Threat of New Entrants
4.2.2 Bargaining Power of Buyers (Hospitals, IDNs)
4.2.3 Bargaining Power of Suppliers
4.2.4 Threat of Substitutes (SAVR)
4.2.5 Competitive Rivalry
4.3 Pricing Trend Analysis (ASP Trends, 2024–2030)
4.4 Value Chain & Supply Chain Analysis
4.5 Regulatory Framework (FDA PMA Pathways, CMS NCD)
4.6 Clinical & Innovation Landscape
4.7 Impact of Digitalization & Imaging Integration
4.8 Impact of Geopolitical & Supply Chain Risks
(What this section provides: Comprehensive industry structure, regulatory, pricing, and competitive intensity analysis)
5. US Transfemoral TAVR Device Market – By Product Type
5.1 Overview
5.2 Segment Share Analysis, 2025 & 2035 (%)
5.3 Balloon-Expandable Valves
5.4 Self-Expanding Valves
5.5 Mechanically Expandable Valves
(What this section provides: Product-level demand trends, clinical preference shifts, and revenue contribution analysis)
6. US Transfemoral TAVR Device Market – By Procedure Setting
6.1 Overview
6.2 Segment Share Analysis, 2025 & 2035 (%)
6.3 Inpatient Settings
6.4 Outpatient / Ambulatory Surgical Centers
(What this section provides: Site-of-care transition insights and cost-efficiency driven adoption patterns)
7. US Transfemoral TAVR Device Market – By Indication Risk Category
7.1 Overview
7.2 Segment Share Analysis, 2025 & 2035 (%)
7.3 Low-Risk Patients
7.4 Intermediate-Risk Patients
7.5 High/Extreme-Risk Patients
(What this section provides: Clinical adoption trends across risk cohorts and future procedural volume drivers)
8. US Transfemoral TAVR Device Market – By End User
8.1 Overview
8.2 Segment Share Analysis, 2025 & 2035 (%)
8.3 Hospitals
8.4 Cardiac Centers
8.5 Ambulatory Surgical Centers
(What this section provides: End-user demand concentration, infrastructure dynamics, and procurement behavior)
9. US Transfemoral TAVR Device Market – By Geography
9.1 Introduction
9.2 Segment Share Analysis, 2025 & 2035 (%)
9.3 West Region
9.3.1 Regional Overview & Trends
9.3.2 Key Manufacturers Presence
9.3.3 Market Size & Forecast by Product Type
9.3.4 Market Size & Forecast by Procedure Setting
9.3.5 Market Size & Forecast by End User
States:
9.3.6 California
9.3.7 Washington
9.3.8 Colorado
9.3.9 Arizona
9.3.10 Oregon
9.3.11 Others
9.3.11.1 Utah
9.3.11.2 Nevada
9.3.11.3 New Mexico
9.3.11.4 Idaho
9.3.11.5 Montana
9.3.11.6 Wyoming
9.3.11.7 Alaska
9.3.11.8 Hawaii
9.4 Northeast Region
9.4.1 Regional Overview & Trends
9.4.2 Market Size & Forecast
States:
9.4.3 New York
9.4.4 Massachusetts
9.4.5 New Jersey
9.4.6 Pennsylvania
9.4.7 Connecticut
9.4.8 Others
9.4.8.1 Maine
9.4.8.2 Vermont
9.4.8.3 New Hampshire
9.4.8.4 Rhode Island
9.4.8.5 Delaware
9.5 South Region
9.5.1 Regional Overview & Trends
9.5.2 Market Size & Forecast
States:
9.5.3 Texas
9.5.4 Florida
9.5.5 Georgia
9.5.6 North Carolina
9.5.7 Tennessee
9.5.8 South Carolina
9.5.9 Alabama
9.5.10 Others
9.5.10.1 Mississippi
9.5.10.2 Louisiana
9.5.10.3 Arkansas
9.5.10.4 Kentucky
9.5.10.5 Oklahoma
9.5.10.6 Virginia
9.5.10.7 Maryland
9.5.10.8 West Virginia
9.6 Midwest Region
9.6.1 Regional Overview & Trends
9.6.2 Market Size & Forecast
States:
9.6.3 Illinois
9.6.4 Ohio
9.6.5 Michigan
9.6.6 Minnesota
9.6.7 Indiana
9.6.8 Wisconsin
9.6.9 Missouri
9.6.10 Others
9.6.10.1 Iowa
9.6.10.2 Kansas
9.6.10.3 Nebraska
9.6.10.4 North Dakota
9.6.10.5 South Dakota
(What this section provides: Granular state-level demand mapping, regional growth hotspots, and investment prioritization insights across the US)
10. US Transfemoral TAVR Device Market: Competitive Landscape & Company Profiles
10.1 Market Share Analysis (2025)
10.2 Company Positioning Matrix
10.3 Company Profiles
10.3.1 Edwards Lifesciences
10.3.2 Medtronic
10.3.3 Abbott Laboratories
10.3.4 Boston Scientific
10.3.5 JenaValve Technology
10.3.6 Meril Life Sciences
10.3.7 MicroPort CardioFlow
10.3.8 Venus Medtech
10.3.9 Anteris Technologies
10.3.10 Foldax
10.3.11 Cardiovalve Ltd.
10.3.12 Peijia Medical
10.3.13 HighLife SAS
10.3.14 Pi-Cardia
10.3.15 4C Medical Technologies
10.3.16 Xeltis
10.3.17 ValveXchange
10.3.18 Vdyne
10.3.19 Terumo Corporation
10.3.20 Siemens Healthineers
10.3.21 GE HealthCare
10.3.22 Philips Healthcare
10.3.23 Canon Medical Systems USA
10.3.24 Abbott Structural Heart Division
10.3.25 Others
(What this section provides: Competitive benchmarking, strategic positioning, and vendor landscape intelligence)
11. US Transfemoral TAVR Device Market: Future Market Outlook (2026–2035)
11.1 Scenario Analysis (Optimistic, Base, Conservative)
11.2 Technology Evolution (Next-Gen Valves, Durability)
11.3 Site-of-Care Transformation
11.4 Emerging Business Models
11.5 Investment & Expansion Opportunities
(What this section provides: Forward-looking insights into market evolution, innovation pathways, and growth scenarios)
12. US Transfemoral TAVR Device Market: Strategic Recommendations
12.1 For Device Manufacturers
12.2 For Hospitals & IDNs
12.3 For Investors
12.4 For New Entrants
(What this section provides: Actionable strategies for stakeholders to maximize market positioning and ROI)
13. US Transfemoral TAVR Device Market: Disclaimer
(What this section provides: Legal framework, data limitations, and usage terms of the report)
List of Tables
TABLE 1: List of Data Sources
TABLE 2: Market Drivers; Impact Analysis
TABLE 3: Market Restraints; Impact Analysis
TABLE 4: US Transfemoral TAVR Device Market: Product Type Snapshot (2025)
TABLE 5: Segment Dashboard; Definition and Scope, by Product Type
TABLE 6: US Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 7: US Transfemoral TAVR Device Market: Procedure Setting Snapshot (2025)
TABLE 8: Segment Dashboard; Definition and Scope, by Procedure Setting
TABLE 9: US Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 10: US Transfemoral TAVR Device Market: Indication Risk Category Snapshot (2025)
TABLE 11: Segment Dashboard; Definition and Scope, by Indication Risk Category
TABLE 12: US Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 13: US Transfemoral TAVR Device Market: End-User Snapshot (2025)
TABLE 14: Segment Dashboard; Definition and Scope, by End-User
TABLE 15: US Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 16: US Transfemoral TAVR Device Market: Regional Snapshot (2025)
TABLE 17: Segment Dashboard; Definition and Scope, by Region
TABLE 18: US Transfemoral TAVR Device Market, by Region, 2021–2035 (USD Million)
TABLE 19: California Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 20: California Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 21: California Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 22: California Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 23: Washington Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 24: Washington Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 25: Washington Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 26: Washington Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 27: Colorado Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 28: Colorado Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 29: Colorado Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 30: Colorado Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 31: Arizona Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 32: Arizona Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 33: Arizona Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 34: Arizona Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 35: Oregon Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 36: Oregon Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 37: Oregon Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 38: Oregon Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 39: West – Others Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 40: West – Others Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 41: West – Others Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 42: West – Others Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
(Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, Hawaii)
TABLE 43: New York Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 44: New York Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 45: New York Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 46: New York Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 47: Massachusetts Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 48: Massachusetts Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 49: Massachusetts Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 50: Massachusetts Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 51: New Jersey Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 52: New Jersey Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 53: New Jersey Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 54: New Jersey Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 55: Pennsylvania Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 56: Pennsylvania Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 57: Pennsylvania Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 58: Pennsylvania Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 59: Connecticut Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 60: Connecticut Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 61: Connecticut Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 62: Connecticut Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 63: Northeast – Others Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 64: Northeast – Others Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 65: Northeast – Others Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 66: Northeast – Others Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
(Maine, Vermont, New Hampshire, Rhode Island, Delaware)
TABLE 67: Texas Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 68: Texas Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 69: Texas Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 70: Texas Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 71: Florida Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 72: Florida Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 73: Florida Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 74: Florida Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 75: Georgia Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 76: Georgia Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 77: Georgia Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 78: Georgia Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 79: North Carolina Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 80: North Carolina Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 81: North Carolina Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 82: North Carolina Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 83: Tennessee Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 84: Tennessee Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 85: Tennessee Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 86: Tennessee Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 87: South Carolina Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 88: South Carolina Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 89: South Carolina Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 90: South Carolina Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 91: Alabama Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 92: Alabama Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 93: Alabama Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 94: Alabama Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 95: South – Others Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 96: South – Others Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 97: South – Others Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 98: South – Others Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
(Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, Virginia, Maryland, West Virginia)
TABLE 99: Illinois Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 100: Illinois Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 101: Illinois Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 102: Illinois Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 103: Ohio Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 104: Ohio Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 105: Ohio Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 106: Ohio Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 107: Michigan Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 108: Michigan Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 109: Michigan Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 110: Michigan Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 111: Minnesota Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 112: Minnesota Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 113: Minnesota Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 114: Minnesota Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 115: Indiana Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 116: Indiana Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 117: Indiana Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 118: Indiana Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 119: Wisconsin Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 120: Wisconsin Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 121: Wisconsin Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 122: Wisconsin Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 123: Missouri Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 124: Missouri Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 125: Missouri Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 126: Missouri Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
TABLE 127: Midwest – Others Transfemoral TAVR Device Market, by Product Type, 2021–2035 (USD Million)
TABLE 128: Midwest – Others Transfemoral TAVR Device Market, by Procedure Setting, 2021–2035 (USD Million)
TABLE 129: Midwest – Others Transfemoral TAVR Device Market, by Indication Risk Category, 2021–2035 (USD Million)
TABLE 130: Midwest – Others Transfemoral TAVR Device Market, by End-User, 2021–2035 (USD Million)
(Iowa, Kansas, Nebraska, North Dakota, South Dakota)
List of Figures
FIGURE 1: US Transfemoral TAVR Device Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis (TAVR Ecosystem)
FIGURE 4: PESTLE Analysis
FIGURE 5: Porter’s Five Forces Analysis
FIGURE 6: Market Attractiveness Analysis
FIGURE 7: Market Dynamics (Drivers, Restraints, Opportunities)
FIGURE 8: Innovation & Patent Landscape in TAVR (2020–2025)
FIGURE 9: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 10: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 11: Product Type Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 12: Procedure Setting Segment Market Share Analysis, 2025 & 2035
FIGURE 13: Procedure Setting Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 14: Indication Risk Category Market Share Analysis, 2025 & 2035
FIGURE 15: Indication Risk Category Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 16: End-User Segment Market Share Analysis, 2025 & 2035
FIGURE 17: End-User Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 18: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 19: Regional Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 20: West Region Transfemoral TAVR Market Share and Leading Players, 2025
FIGURE 21: Northeast Region Transfemoral TAVR Market Share and Leading Players, 2025
FIGURE 22: South Region Transfemoral TAVR Market Share and Leading Players, 2025
FIGURE 23: Midwest Region Transfemoral TAVR Market Share and Leading Players, 2025
FIGURE 24: West Region Market Share Analysis by State, 2025
FIGURE 25: California Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 26: Washington Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 27: Colorado Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 28: Arizona Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 29: Oregon Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 30: Others (West Region) Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 31: South Region Market Share Analysis by State, 2025
FIGURE 32: Texas Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 33: Florida Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 34: Georgia Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 35: North Carolina Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 36: Tennessee Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 37: South Carolina Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 38: Alabama Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 39: Others (South Region) Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 40: Midwest Region Market Share Analysis by State, 2025
FIGURE 41: Illinois Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 42: Ohio Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 43: Michigan Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 44: Minnesota Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 45: Indiana Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 46: Wisconsin Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 47: Missouri Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 48: Others (Midwest Region) Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 49: Northeast Region Market Share Analysis by State, 2025
FIGURE 50: New York Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 51: Massachusetts Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 52: New Jersey Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 53: Pennsylvania Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 54: Connecticut Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 55: Others (Northeast Region) Transfemoral TAVR Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
1. How large is the addressable patient pool for transfemoral TAVR in the US?
Approximately 1.5–1.8 million patients in the US suffer from severe aortic stenosis, with nearly 700,000+ currently eligible for TAVR, and over 90% suitable for transfemoral access, making it the primary procedural pathway.
2. What is driving the shift from surgical AVR (SAVR) to transfemoral TAVR?
Clinical trials show TAVR reduces hospital stay by ~50% and mortality/readmission rates by 10–15% in selected cohorts, while offering faster recovery—leading to >75% share of all aortic valve replacements in the US by 2025.
3. How significant is the low-risk patient segment for future growth?
Low-risk patients are expected to account for over 60% of total TAVR volumes by 2030, compared to less than 25% in 2019, making it the single largest volume expansion driver.
4. What is the average selling price (ASP) trend for TAVR devices in the US?
Current ASPs range between $28,000–$34,000 per valve, with gradual pricing pressure of ~1–2% annually, offset by increased procedural volumes and premium pricing for next-gen valves.
5. How are hospitals financially benefiting from transfemoral TAVR programs?
Hospitals achieve 20–30% higher procedural throughput and reduced ICU utilization by up to 70%, improving margins under DRG payments, especially in high-volume centers performing 300+ procedures annually.
6. What role does outpatient TAVR play in market expansion?
Outpatient or same-day discharge TAVR is projected to grow at >15% CAGR, with leading centers already discharging 25–30% of patients within 24 hours, significantly lowering cost per case.
7. How concentrated is the competitive landscape?
The market is highly concentrated, with Edwards Lifesciences and Medtronic controlling ~85–90% of US market share, though emerging players are targeting niche indications like aortic regurgitation and valve durability.
8. What are the key clinical limitations impacting long-term adoption?
Durability beyond 10–15 years remains under evaluation, particularly for younger patients (<65 years), creating uncertainty around lifetime valve management strategies and repeat interventions.
9. Which US regions are generating the highest procedural volumes?
States like California, Florida, Texas, and New York collectively contribute over 40% of total US TAVR procedures, driven by high elderly populations and dense structural heart programs.
10. What is the long-term strategic opportunity for device manufacturers?
The biggest opportunity lies in lifetime valve management, including valve-in-valve procedures, next-gen durability innovations, and digital integration—potentially expanding lifetime patient value by 2–3x per case.
